Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "MEA"

1111 News Found

CKD cases surge to 16.38% in Indians aged 15+
Healthcare | March 17, 2025

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care


Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals
Opinion | March 17, 2025

Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant


Azelis signs distribution agreement with Evonik to expands pharmaceutical offering in Malaysia and Singapore
Supply Chain | March 13, 2025

Azelis signs distribution agreement with Evonik to expands pharmaceutical offering in Malaysia and Singapore

This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific


Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


UFlex secures USFDA approval for recycled PE in food packaging
Packaging | March 12, 2025

UFlex secures USFDA approval for recycled PE in food packaging

Announces Rs. 317 crore investment in new recycling plant


Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics
News | March 10, 2025

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise


Biocon Biologics announces positive results from Phase 3 study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis
Diagnostic Center | March 08, 2025

Biocon Biologics announces positive results from Phase 3 study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis

The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara